EPS8L2: A Potential Drug Target and Biomarker for the Epidermal Growth Factor Receptor Pathway

Target Name: EPS8L2

NCBI ID: G64787

EPS8L2

EPS8L2: A Potential Drug Target and Biomarker for the Epidermal Growth Factor Receptor Pathway

The epidermal growth factor receptor (EGFR) is a transmembrane protein that plays a crucial role in cell signaling, particularly in the regulation of cell proliferation and survival. The EGFR signaling pathway is a highly conserved and highly targeted pathway, and is involved in the development and maintenance of various diseases, including cancer. Therefore, targeting the EGFR signaling pathway has become an attractive research focus in recent years.

EPS8L2: A Potential Drug Target

EPS8L2, a 21-kDa protein, was identified as a potential drug target in the EGFR signaling pathway. EPS8L2 is a component of the EGFR signaling pathway and has been shown to play a critical role in the regulation of cell growth, angiogenesis, and cancer progression.

In cancer, EPS8L2 has been shown to promote the growth and survival of various cancer cell types, including breast, lung, and colorectal cancer. EPS8L2 has also been shown to contribute to the development and progression of various types of cancer, including neuroendocrine tumors, melanoma, and sarcoma.

As a potential drug target, EPS8L2 has the potential to be a valuable therapeutic agent for the treatment of various types of cancer. For example, in breast cancer, EPS8L2 has been shown to promote the growth and survival of human breast cancer cells, and may be a useful target for anti-cancer drugs that target the EGFR signaling pathway.

EPS8L2: A Potential Biomarker

In addition to its potential as a drug target, EPS8L2 may also be a useful biomarker for the diagnosis and monitoring of various types of cancer. For example, EPS8L2 has been shown to be expressed in various types of cancer, including breast, lung, and colorectal cancer. Therefore, measuring the levels of EPS8L2 in cancer cells or tissues may be a useful diagnostic tool for cancer diagnosis.

EPS8L2 has also been shown to be a potential biomarker for the evaluation of cancer progression and response to therapy. For example, EPS8L2 has been shown to be expressed in the serum of patients with breast cancer, and has been shown to be a useful biomarker for the evaluation of response to chemotherapy.

Conclusion

In conclusion, EPS8L2 is a potential drug target and biomarker for the EGFR signaling pathway. EPS8L2 has been shown to promote the growth and survival of various cancer cell types and has the potential to be a valuable therapeutic agent for the treatment of cancer. Further research is needed to fully understand the role of EPS8L2 in cancer biology and to develop effective therapies that target the EGFR signaling pathway.

Protein Name: EPS8 Like 2

Functions: Stimulates guanine exchange activity of SOS1. May play a role in membrane ruffling and remodeling of the actin cytoskeleton. In the cochlea, is required for stereocilia maintenance in adult hair cells (By similarity)

The "EPS8L2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EPS8L2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets